Drugs / GNC-038
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06857214 | Jun 2025 → Dec 2027 expected | systemic lupus erythematosus | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06857227 | Mar 2025 → Dec 2027 expected | rheumatoid arthritis | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT04606433 | Nov 2020 → Dec 2025 overdue | acute lymphoblastic leukemia | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05627856 | Feb 2023 → Dec 2025 overdue | T-cell and NK-cell neoplasm, T-cell non-Hodgkin lymphoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05485753 | Feb 2023 → Dec 2025 overdue | central nervous system non-hodgkin lymphoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05623982 | Sep 2022 → Dec 2026 expected | non-Hodgkin lymphoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05192486 | Aug 2022 → Dec 2025 overdue | diffuse large B-cell lymphoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNC-038 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05485753 ↗ |
| Modality | Monoclonal antibody | “GNC-038 Tetra-specific Antibody Injection” NCT06857214 ↗ |
| Route | Intravenous | “Administration by intravenous infusion.” NCT04606433 ↗ |